GGrantIndex
← Leaderboards

Gregory John Tobin

Biological Mimetics, Inc.

$10,932,769
Attributed
$10,932,769
Total exposure
9
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,932,769 · 9

By mechanism

R44$7,273,546 · 2
R43$2,160,582 · 6
N43$1,498,641 · 1

Top collaborators

No co-investigators on record.

Most similar at Biological Mimetics, Inc.

Same institution · by research overlap

Others in their field

Top investigators on “Future

Research focus

FutureVirusProductionTechnologyPathogenEngineeringVaccinesImmunogenicityEpitopesSiteDoseSerumDesignAnimalsNeutralizing AntibodyInfectionClinical TrialsPreparationBaseRunningLicensingSafetyImmunizationProteins

Grant awards (17)

FAST – CRISPR-based Diagnostic for Parasites$1,498,641
N43 · FY2025 · AI · contact PI
An instrument-free malaria diagnostic$291,139
R43 · FY2025 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$917,012
R44 · FY2024 · AI · contact PI
An instrument-free malaria diagnostic$297,761
R43 · FY2024 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$976,542
R44 · FY2023 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$990,662
R44 · FY2022 · AI · contact PI
Development of a cross-protective HRV vaccine$224,958
R43 · FY2019 · AI · contact PI
Development of an improved, low-cost polio vaccine (Ir-IPV)$723,136
R44 · FY2018 · AI · contact PI
Manganese-peptide Countermeasures for Radiation Exposure$299,372
R43 · FY2018 · AI · contact PI
Improved RSV F Vaccine Candidates$224,956
R43 · FY2018 · AI · contact PI
Development of an improved, low-cost polio vaccine (Ir-IPV)$743,104
R44 · FY2017 · AI · contact PI
Development of the first HRV vaccine$999,998
R44 · FY2016 · AI · contact PI
Development of the first HRV vaccine$999,998
R44 · FY2015 · AI · contact PI
Development of a New Low-Cost Poliovirus Vaccine (Ir-IPV): Feasibility study with PV-2$224,887
R43 · FY2015 · AI · contact PI
Development of the first HRV vaccine$923,094
R44 · FY2014 · AI · contact PI
Development of a novel human rhinovirus vaccine$299,164
R43 · FY2011 · AI · contact PI
Development of a novel human rhinovirus vaccine$298,345
R43 · FY2010 · AI · contact PI